ArticleJournal of clinical medicine2020
Long-Term Treatment Outcome of Progressive
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Management of Adult Bronchiectasis: Consensus-Based Guidelines of the German Respiratory Society.Respiration; international review of thoracic diseases · 2026Guideline
- Fatal Persistent Cavitary Mycobacterium avium Complex Pulmonary Disease in a Non-HIV Patient With Prior Malignancy.Cureus · 2026Article
- Radiologic phenotype-specific transcriptomic signatures in lung tissues from patients with Mycobacterium avium complex pulmonary disease.European journal of medical research · 2026Article
- Early treatment interruption and nutritional status as predictors of mortality in Mycobacterium avium complex pulmonary disease.PloS one · 2026Article
- Clinical efficacy of sitafloxacin-containing regimens for Mycobacterium avium complex pulmonary disease.BMC pulmonary medicine · 2025Article
- Comparative immunophenotyping of peripheral blood lymphocyte subsets in pulmonary tuberculosis and nontuberculous mycobacterial pulmonary disease: a retrospective study.Frontiers in immunology · 2025Article
- Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation.BMC pulmonary medicine · 2024Article
- Article
- The Clinical Implications of Serum Carbohydrate Antigen 19-9 Levels in Patients with Nontuberculous Mycobacteria Pulmonary Disease.Journal of clinical medicine · 2023Article
- Treatment outcomes and relapse in patients withMicrobiology spectrum · 2023Article
- Virulence of Mycobacterium intracellulare clinical strains in a mouse model of lung infection - role of neutrophilic inflammation in disease severity.BMC microbiology · 2023Article
- Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in RefractoryInfection and drug resistance · 2023Article
- Long-Term Prognosis and Antimycobacterial Glycolipid Antibody as Biomarker in Mycobacterium avium-intracellulare Complex Pulmonary Disease.Microbiology spectrum · 2022Observational
- Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.Antimicrobial agents and chemotherapy · 2022Article
- Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity.Scientific reports · 2022Article
- A Low Body Mass Index Is Associated with Unsuccessful Treatment in Patients withJournal of clinical medicine · 2021Article
- New/Different Look at the Presence ofMicroorganisms · 2021Article
- First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease.Scientific reports · 2021Article
- Differences in the clinical characteristics of chronic pulmonary aspergillosis according to spirometric impairment.PloS one · 2021Article
- Pleuroparenchymal fibroelastosis inERJ open research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMultidrug therapy is essential for preventing respiratory failure in patients with highly progressive
methodsWe retrospectively evaluated the clinical characteristics and long-term outcomes in patients with chemo-naïve progressive MAC-PD, hospitalized for first-line multidrug therapy.
resultsAmong 125 patients, 86 (68.8%) received standardized treatment (rifampicin, ethambutol, clarithromycin), 25 (20.0%) received a fluoroquinolone (FQ)-containing regimen, and 53 (42.4%) received aminoglycoside injection. The sputum conversion rate was 80.0%, and was independently associated with standardized treatment. The incidence of refractory disease (45.6%) was independently and negatively associated with standardized regimen and aminoglycoside use. Choice of an FQ-containing regimen was not associated with positive outcome. Clarithromycin resistance occurred in 16.8% and was independently associated with refractory disease. MAC-PD-associated death occurred in 3.3% of patients with non-cavitary nodular bronchiectasis (NB) and 21.3% with cavitary MAC-PD over a median follow-up period of 56.4 months. The rates of MAC-PD-associated death were comparable between cavitary-NB and fibrocavitary disease. Concurrent chronic pulmonary aspergillosis (CPA) occurred in 13 (17.3%) patients with cavitary MAC-PD, and age, diabetes mellitus, and CPA were independent risk factors for mortality.
conclusionsStandardized intensive multidrug treatment reduces disease progression and persistence in progressive MAC-PD. Cavitary NB may differ from, rather than being just an advanced stage of, non-cavitary NB. The high incidence and significant mortality of CPA in cavitary MAC-PD highlight the need for early diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.